NERV

Minerva Neurosciences Inc Common Stock (NERV)

Stock · NASDAQ · Health Care

$2.35as of 10/16/2026

Active signals

Resistance level
$3.97
Industry
Biotechnology: Pharmaceutical Preparations

What NERV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike44-1.3%45%
Bollinger Band Breakout27-7.6%37%
Bollinger Band Breakdown19-5.1%47%
200-Day Moving Average TouchActive now8-2.1%38%
Any 20-session window (baseline)-1.6%47%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
7

Fundamentals

1-day range
$2.3$2.47
Market cap
$206.85M
P/E (trailing)
—
P/E (forward)
-5.58
EPS (trailing)
$-28.45
Dividend yield
—
Beta
0.04
Avg. volume
183.0K
52-week range
$2.31$12.46
Next earnings: August 5, 2025 · EPS estimate $-0.90confirmed

How Minerva Neurosciences Inc Common Stock Makes Money

Where the revenue actually goes — FY2020 annual results

market-wall.comTotalRevenue$41.18MNet Income$1.94M (5%)R&D$22.04M (54%)SG&A$17.29M (42%)NERV

Source: 10-K filed Mar 8, 2021 · via SEC EDGAR / Finnhub

Operating Income$1.85M(4%)

Forecasts

3 analyst ratings

Buy 78%
Hold 22%
Sell 0%
1-year price forecast
High
$14
+495.7%
Median
$10
+325.5%
Low
$7
+197.9%

Minerva Neurosciences Inc Common Stock Competitors

Chosen by industry and closest market cap.

  • NERV
    Minerva Neurosciences Inc Common Stock
    $2.35
    ▼ 2.89%
    Market cap $206.85MP/E —
    $2.31$12.46
  • GLSI
    Greenwich LifeSciences Inc. Common Stock
    $14.55
    ▼ 5.03%
    Market cap $209.02MP/E —
    $7.78$34.1
  • MSLE
    Satellos Bioscience Inc. Common Stock
    $6.46
    ▼ 5.56%
    Market cap $209.77MP/E —
    $7.56$18.98
  • KROS
    Keros Therapeutics Inc. Common Stock
    $10.66
    ▼ 3.96%
    Market cap $211.16MP/E —
    $9.69$22.55
  • IMUX
    Immunic Inc. Common Stock
    $6.97
    ▼ 1.83%
    Market cap $198.06MP/E —
    $5.06$17.43
  • NBP
    NovaBridge Biosciences American Depositary Shares
    $1.26
    ▼ 2.33%
    Market cap $196.15MP/E —
    $1.26$6.79
  • ANTX
    AN2 Therapeutics Inc. Common Stock
    $3.38
    ▼ 6.11%
    Market cap $218.98MP/E —
    $1$7.19

P/E shows — for peers not currently carrying a live signal of their own.

Insider Activity

Insider Actions →
Acquired
2.98M
Disposed
0
  • Kaul Inderjit · August 3, 2026 · Grant
    12.1K
  • Kaul Inderjit · June 3, 2026 · Grant
    50.0K
  • Kupfer David · June 3, 2026 · Grant
    50.0K
  • Laghrissi-Thode Fouzia · June 3, 2026 · Grant
    50.0K
  • Remy Luthringer · June 3, 2026 · Grant
    1.69M
  • Frederick W. Ahlholm · June 3, 2026 · Grant
    680.0K
  • HASLER HANS PETER · June 3, 2026 · Grant
    50.0K
  • VAN HEEK G JAN · June 3, 2026 · Grant
    50.0K
  • O'Connor James Joseph · April 21, 2026 · Grant
    350.8K

Institutional Ownership

March 31, 2026

Total shares held
38.01M
Total value held
$229.01M
Institutional holders
42
Top holders this quarter
  • Unknown5.11M
  • Unknown4.32M
  • Unknown4.29M
  • Unknown4.26M
  • Unknown3.21M
  • Unknown2.37M
  • Unknown1.99M
  • Unknown1.85M
  • Unknown1.66M
  • Unknown1.66M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.